A. Almasan and A. Ashkenazi, Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy, Cytokine & Growth Factor Reviews, vol.14, issue.3-4, pp.337-348, 2003.
DOI : 10.1016/S1359-6101(03)00029-7

A. Arcaro, C. Gregoire, T. R. Bakker, L. Baldi, M. Jordan et al., Complexes, The Journal of Experimental Medicine, vol.161, issue.10, pp.1485-1495, 2001.
DOI : 10.1038/384484a0

A. Ashkenazi, R. C. Pai, S. Fong, S. Leung, D. A. Lawrence et al., Safety and antitumor activity of recombinant soluble Apo2 ligand, Journal of Clinical Investigation, vol.104, issue.2, pp.155-162, 1999.
DOI : 10.1172/JCI6926

K. M. Boatright, M. Renatus, F. L. Scott, S. Sperandio, H. Shin et al., A Unified Model for Apical Caspase Activation, Molecular Cell, vol.11, issue.2, pp.529-541, 2003.
DOI : 10.1016/S1097-2765(03)00051-0

J. L. Bodmer, N. Holler, S. Reynard, P. Vinciguerra, P. Schneider et al., TRAIL receptor-2 signals apoptosis through FADD and caspase-8, Nat. Cell Biol, vol.2, pp.241-243, 2000.

S. Bouralexis, D. M. Findlay, G. J. Atkins, A. Labrinidis, S. Hay et al., Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy, British Journal of Cancer, vol.164, issue.1, pp.206-214, 2003.
DOI : 10.1016/S0014-5793(00)02042-1

P. M. Chaudhary, M. Eby, A. Jasmin, A. Bookwalter, J. Murray et al., Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-??B Pathway, Immunity, vol.7, issue.6, pp.821-830, 1997.
DOI : 10.1016/S1074-7613(00)80400-8

L. Clancy, K. Mruk, K. Archer, M. Woelfel, J. Mongkolsapaya et al., Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis, Proc. Natl. Acad. Sci. USA, pp.18099-18104, 2005.
DOI : 10.1073/pnas.0507329102

I. A. Davidovich, A. S. Levenson, and V. V. Chernokhvostov, Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance, Cancer Letters, vol.211, issue.2, pp.189-197, 2004.
DOI : 10.1016/j.canlet.2004.03.026

M. A. Degli-esposti, W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith et al., The Novel Receptor TRAIL-R4 Induces NF-??B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain, Immunity, vol.7, issue.6, pp.813-820, 1997.
DOI : 10.1016/S1074-7613(00)80399-4

M. A. Degli-esposti, P. J. Smolak, H. Walczak, J. Waugh, C. P. Huang et al., Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family, The Journal of Experimental Medicine, vol.268, issue.7, pp.1165-1170, 1997.
DOI : 10.1016/0008-8749(91)90062-G

T. S. Griffith, W. A. Chin, G. C. Jackson, D. H. Lynch, and M. , Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells, Z. Kubin. J. Immunol, vol.161, pp.2833-2840, 1998.

T. S. Griffith, C. T. Rauch, P. J. Smolak, J. Y. Waugh, N. Boiani et al., Functional analysis of TRAIL receptors using monoclonal antibodies, Z. Kubin. J. Immunol, vol.162, pp.2597-2605, 1999.

T. Gura, CANCER RESEARCH: How TRAIL Kills Cancer Cells, But Not Normal Cells, Science, vol.277, issue.5327, p.768, 1997.
DOI : 10.1126/science.277.5327.768

P. Horak, D. Pils, G. Haller, I. Pribill, M. Roessler et al., Contribution of Epigenetic Silencing of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer, Molecular Cancer Research, vol.3, issue.6, pp.335-343, 2005.
DOI : 10.1158/1541-7786.MCR-04-0136

F. H. Igney and P. H. Krammer, DEATH AND ANTI-DEATH: TUMOUR RESISTANCE TO APOPTOSIS, Nature Reviews Cancer, vol.2, issue.4, pp.277-288, 2002.
DOI : 10.1038/nrc776

T. G. Jin, A. Kurakin, N. Benhaga, K. Abe, M. Mohseni et al., Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5, Journal of Biological Chemistry, vol.279, issue.53, pp.55594-55601, 2004.
DOI : 10.1074/jbc.M401056200

R. W. Johnstone, A. A. Ruefli, and S. W. Lowe, Apoptosis, Cell, vol.108, issue.2, pp.153-164, 2002.
DOI : 10.1016/S0092-8674(02)00625-6

T. Kataoka, M. Schroter, M. Hahne, P. Schneider, M. Irmler et al., FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation, J. Immunol, vol.161, pp.3936-3942, 1998.

R. F. Kelley, K. Totpal, S. H. Lindstrom, M. Mathieu, K. Billeci et al., Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling, Journal of Biological Chemistry, vol.280, issue.3, pp.2205-2212, 2005.
DOI : 10.1074/jbc.M410660200

S. K. Kelley, L. A. Harris, D. Xie, L. Deforge, K. Totpal et al., Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety, J. Pharmacol. Exp. Ther, vol.299, pp.31-38, 2001.

H. N. Leblanc and A. Ashkenazi, Apo2L/TRAIL and its death and decoy receptors, Cell Death and Differentiation, vol.10, issue.1, pp.66-75, 2003.
DOI : 10.1038/sj.cdd.4401187

H. W. Lee, S. H. Lee, H. W. Lee, Y. W. Ryu, M. H. Kwon et al., Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors, Biochemical and Biophysical Research Communications, vol.330, issue.4, pp.1205-1212, 2005.
DOI : 10.1016/j.bbrc.2005.03.101

D. F. Legler, O. Micheau, M. A. Doucey, J. Tschopp, and C. Bron, Recruitment of TNF Receptor 1 to Lipid Rafts Is Essential for TNF??-Mediated NF-??B Activation, Immunity, vol.18, issue.5, pp.655-664, 2003.
DOI : 10.1016/S1074-7613(03)00092-X

X. Liu, P. Yue, F. R. Khuri, and S. Y. Sun, Decoy Receptor 2 (DcR2) Is a p53 Target Gene and Regulates Chemosensitivity, Cancer Research, vol.65, issue.20, pp.9169-9175, 2005.
DOI : 10.1158/0008-5472.CAN-05-0939

M. Macfarlane, M. Ahmad, S. M. Srinivasula, T. Fernandes-alnemri, G. M. Cohen et al., Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL, Journal of Biological Chemistry, vol.272, issue.41, pp.25417-25420, 1997.
DOI : 10.1074/jbc.272.41.25417

M. Macfarlane, S. Inoue, S. L. Kohlhaas, A. Majid, N. Harper et al., Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1, Cell Death and Differentiation, vol.89, issue.7, pp.773-782, 2005.
DOI : 10.1038/sj.leu.2403202

O. Micheau, Cellular FLICE-inhibitory protein: an attractive therapeutic target?, Expert Opinion on Therapeutic Targets, vol.62, issue.279, pp.559-573, 2003.
DOI : 10.4161/cbt.1.1.45
URL : https://hal.archives-ouvertes.fr/inserm-00527112

O. Micheau, S. Lens, O. Gaide, K. Alevizopoulos, and J. Tschopp, NF-??B Signals Induce the Expression of c-FLIP, Molecular and Cellular Biology, vol.21, issue.16, pp.5299-5305, 2001.
DOI : 10.1128/MCB.21.16.5299-5305.2001

O. Micheau, M. Thome, P. Schneider, N. Holler, J. Tschopp et al., The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex, Journal of Biological Chemistry, vol.277, issue.47, pp.45162-45171, 2002.
DOI : 10.1074/jbc.M206882200

G. Pan, J. Ni, Y. F. Wei, G. Yu, R. Gentz et al., An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL, Science, vol.277, issue.5327, pp.815-818, 1997.
DOI : 10.1126/science.277.5327.815

G. Pan, K. O-'rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner et al., The Receptor for the Cytotoxic Ligand TRAIL, Science, vol.276, issue.5309, pp.111-113, 1997.
DOI : 10.1126/science.276.5309.111

R. Riccioni, L. Pasquini, G. Mariani, E. Saulle, A. Rossini et al., TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL, Haematologica, vol.90, pp.612-624, 2005.

E. Rimondi, P. Secchiero, A. Quaroni, C. Zerbinati, S. Capitani et al., Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation, Journal of Cellular Physiology, vol.21, issue.3, pp.647-654, 2006.
DOI : 10.1002/jcp.20512

A. D. Sanlioglu, E. Dirice, C. Aydin, N. Erin, S. Koksoy et al., Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells, BMC Cancer, vol.273, issue.1, p.54, 2005.
DOI : 10.1074/jbc.273.45.29411

P. Schneider, Production of Recombinant TRAIL and TRAIL Receptor: Fc Chimeric Proteins, Methods Enzymol, vol.322, pp.325-345, 2000.
DOI : 10.1016/S0076-6879(00)22031-4

D. A. Sharp, D. A. Lawrence, and A. Ashkenazi, Selective Knockdown of the Long Variant of Cellular FLICE Inhibitory Protein Augments Death Receptor-mediated Caspase-8 Activation and Apoptosis, Journal of Biological Chemistry, vol.280, issue.19, pp.19401-19409, 2005.
DOI : 10.1074/jbc.M413962200

P. Goddard, A. Godowski, and . Ashkenazi, Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors, Science, vol.277, pp.818-821, 1997.

M. R. Sprick, E. Rieser, H. Stahl, A. Grosse-wilde, M. A. Weigand et al., Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8, The EMBO Journal, vol.21, issue.17, pp.4520-4530, 2002.
DOI : 10.1093/emboj/cdf441

K. Takeda, N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa et al., Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy, The Journal of Experimental Medicine, vol.62, issue.4, pp.437-448, 2004.
DOI : 10.1074/jbc.M210665200

A. Thorburn, Death receptor-induced cell killing, Cellular Signalling, vol.16, issue.2, pp.139-144, 2004.
DOI : 10.1016/j.cellsig.2003.08.007

E. Varfolomeev, H. Maecker, D. Sharp, D. Lawrence, M. Renz et al., Molecular Determinants of Kinase Pathway Activation by Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand, Journal of Biological Chemistry, vol.280, issue.49, pp.40599-40608, 2005.
DOI : 10.1074/jbc.M509560200

C. Vermot-desroches, E. Sergent, B. Bonnin, and J. Wijdenes, Characterization of monoclonal antibodies directed against trail or trail receptors, Cellular Immunology, vol.236, issue.1-2, pp.86-91, 2005.
DOI : 10.1016/j.cellimm.2005.08.012

H. Wajant, J. Gerspach, and K. Pfizenmaier, Tumor therapeutics by design: targeting and activation of death receptors, Cytokine & Growth Factor Reviews, vol.16, issue.1, pp.55-76, 2005.
DOI : 10.1016/j.cytogfr.2004.12.001

C. T. Goodwin and . Rauch, TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL, EMBO J, vol.16, pp.5386-5397, 1997.

H. Walczak, R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith et al., Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat. Med, vol.5, pp.157-163, 1999.

C. Y. Wang, M. W. Mayo, R. G. Korneluk, D. V. Goeddel, A. S. Baldwin et al., NF-B Antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to Suppress Caspase-8 Activation, Science, vol.281, issue.5383, pp.1680-1683, 1998.
DOI : 10.1126/science.281.5383.1680

C. H. Weber and C. Vincenz, A docking model of key components of the DISC complex: death domain superfamily interactions redefined, FEBS Letters, vol.103, issue.3, pp.171-176, 2001.
DOI : 10.1016/S0014-5793(01)02162-7

J. Zhang, D. Cado, A. Chen, N. H. Kabra, and A. Winoto, Fasmediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1, Nature, vol.392, pp.296-300, 1998.

X. D. Zhang, T. Nguyen, W. D. Thomas, J. E. Sanders, and P. Hersey, Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types, FEBS Letters, vol.161, issue.3, pp.193-199, 2000.
DOI : 10.1016/S0014-5793(00)02042-1